미국의 피임약 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2026-2033년)

U.S. Contraceptive Market Summary

The U.S. contraceptive market size was valued at USD 8.4 billion in 2025 and is expected to reach USD 12.4 billion by 2033, growing at a CAGR of 4.9% from 2026 to 2033. The increase in the use of modern contraceptives and the rise in awareness among adolescents and young people about sexual health and family planning are key factors driving the U.S. market growth.

Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers. The section below outlines key market factors such as research and development and trends shaping the women's contraceptive health market. It highlights recent product launches, regulatory approvals, public health initiatives, and technological innovations that are expanding contraceptive choices, improving accessibility, and driving market growth in the U.S.

U.S. Contraceptive Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. contraceptive market report based on product and region.

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Pills
• Intrauterine Devices (IUD)
  • Hormonal IUD
  • Nonhormonal IUD
• Condoms
  • Male Condoms
  • Female Condoms
• Vaginal Ring
• Subdermal Implants
• Injectable
• Others
• Region Outlook (Revenue, USD Billion, 2021 - 2033)
• West
• Southeast
• Southwest
• Northeast
• Midwest

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
  • 1.4.6. Research Assumption
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. Objectives
  • 1.8.1. Objective - 1
  • 1.8.2. Objective - 2
  • 1.8.3. Objective - 3
• 1.9. List of Secondary Sources
• 1.10. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. U.S. Contraceptive Market
  • 2.1.1. Market Snapshot
  • 2.1.2. Segment Snapshot
    • 2.1.2.1. Product segment outlook
  • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Regulatory Framework
• 3.5. Business Environment Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. U.S. Contraceptive Market: Product Movement Analysis
• 4.2. U.S. Contraceptive Market: Product Segment Dashboard
• 4.3. Product Movement & Market Share Analysis, 2025 & 2033
• 4.4. U.S. Contraceptive Market Estimates & Forecast, by Product
• 4.5. Pills
  • 4.5.1. Pills Market, 2021 - 2033 (USD Million)
• 4.6. Intrauterine Devices (IUD)
  • 4.6.1. Intrauterine Devices (IUD) Market, 2021 - 2033 (USD Million)
  • 4.6.2. Hormonal IUD
    • 4.6.2.1. Hormonal IUD market, 2021 - 2033 (USD Million)
  • 4.6.3. Nonhormonal IUD
    • 4.6.3.1. Nonhormonal IUD market, 2021 - 2033 (USD Million)
• 4.7. Condoms
  • 4.7.1. Condoms Market, 2021 - 2033 (USD Million)
  • 4.7.2. Male Condoms
    • 4.7.2.1. Male condoms market, 2021 - 2033 (USD Million)
  • 4.7.3. Female Condoms
    • 4.7.3.1. Female condoms market, 2021 - 2033 (USD Million)
• 4.8. Vaginal Ring
  • 4.8.1. Vaginal Ring Market, 2021 - 2033 (USD Million)
• 4.9. Subdermal Implants
  • 4.9.1. Subdermal Implants Market, 2021 - 2033 (USD Million)
• 4.10. Injectable
  • 4.10.1. Injectable Market, 2021 - 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Region Business Analysis

• 5.1. U.S. Contraceptive Market: Region Movement Analysis
• 5.2. U.S. Contraceptive Market: Region Segment Dashboard
• 5.3. Region Movement & Market Share Analysis, 2025 & 2033
• 5.4. U.S. Contraceptive Market Estimates & Forecast, by Region
• 5.5. West
  • 5.5.1. West Market, 2021 - 2033 (USD Million)
• 5.6. Southeast
  • 5.6.1. Southeast Market, 2021 - 2033 (USD Million)
• 5.7. Southwest
  • 5.7.1. Southwest Market, 2021 - 2033 (USD Million)
• 5.8. Northeast
  • 5.8.1. Northeast Market, 2021 - 2033 (USD Million)
• 5.9. Midwest
  • 5.9.1. Midwest Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Company Market Position Analysis, 2025
• 6.3. Strategy Mapping
  • 6.3.1. Mergers & Acquisitions
  • 6.3.2. Partnership and Collaborations
  • 6.3.3. New Product Launch
  • 6.3.4. Others
• 6.4. Company Profiles/Listing
  • 6.4.1. Church & Dwight Co., Inc.
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Reckitt Benckiser Group Plc
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Organon Group of Companies
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Pfizer, Inc.
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Teva Pharmaceutical Industries Ltd.
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. The Cooper Companies, Inc.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Mayer Laboratories Inc
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Agile Therapeutics
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Mayne Pharma Group Limited.
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Product benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Bayer AG
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Product benchmarking
    • 6.4.10.4. Strategic initiatives
  • 6.4.11. Afaxys, Inc.
    • 6.4.11.1. Overview
    • 6.4.11.2. Financial performance
    • 6.4.11.3. Product benchmarking
    • 6.4.11.4. Strategic initiatives
  • 6.4.12. AbbVie
    • 6.4.12.1. Overview
    • 6.4.12.2. Financial performance
    • 6.4.12.3. Product benchmarking
    • 6.4.12.4. Strategic initiatives
  • 6.4.13. Gedeon Richter
    • 6.4.13.1. Overview
    • 6.4.13.2. Financial performance
    • 6.4.13.3. Product benchmarking
    • 6.4.13.4. Strategic initiatives